RE:IPFGreat post, Mitch. I am hoping that the next read out from the IPF study will convince the market that 4050 is going to become the next standard of care drug for IPF. The issue will be which of the two existing drugs best combines with 4050? Based on animal studies it is Esbriet so it will be interesting to see if the human studies reach a similar conclusion. Clearly, both Roche and Boehringer must be following developments very closely.